SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on July 18, 2002; DOI 10.1182/blood-2002-01-0222. This Article Full Text Full Text (PDF) All Versions of this Article: 2002-01-0222v1 100/12/3887    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ogata, K. Articles by Yoshida, Y. Search for Related Content PubMed PubMed Citation Articles by Ogata, K. Articles by Yoshida, Y. Related Collections Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 December 2002, Vol. 100, No. 12, pp. 3887-3896 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome Kiyoyuki Ogata, Kyoko Nakamura, Norio Yokose, Hideto Tamura, Mikiko Tachibana, Osamu Taniguchi, Rika Iwakiri, Tatsuyuki Hayashi, Hisashi Sakamaki, Yoshiro Murai, Kaoru Tohyama, Shigeru Tomoyasu, Yasunobu Nonaka, Mayumi Mori, Kazuo Dan, and Yataro Yoshida From the Division of Hematology, Nippon Medical School, Hematonosis Cell Analysis Center, Otsuka Assay Laboratories, Division of Hematology, Tokyo Metropolitan Geriatric Hospital, Division of Hematology, Tokyo Metropolitan Police Hospital, Division of Hematology, Tokyo Metropolitan Komagome Hospital, Division of Hematology, Tokyo Metropolitan Tama Geriatric Hospital, Division of Hematology, Showa University, Tokyo, Japan; Division of Hematology, Kyoto University, and Division of Hematology, Takeda Hospital, Kyoto, Japan. Knowledge of the blast phenotype in myelodysplastic syndrome (MDS) would be valuable, as in other malignancies, but remains sparse. This is mainly because MDS blasts are a minor population in clinical samples, making analysis difficult. Thus, for this blast phenotype study, we prepared blast-rich specimens (using a new density centrifugation reagent for harvesting blasts) from blood and marrow samples of 95 patients with various MDS subtypes and 21 patients with acute leukemia transformed from MDS (AL-MDS). Flow cytometry revealed that a high proportion of the enriched blast cells (EBCs) from almost all patients showed an immunophenotype of committed myeloid precursors (CD34+CD38+HLA-DR+CD13+CD33+), regardless of the disease subtype. The cytochemical reaction for myeloperoxidase was negative in 58% of the cases. Thus, the EBC phenotype is more immature in MDS than in de novo acute myeloid leukemia. MDS EBCs often coexpressed stem cell antigens and late-stage myeloid antigens asynchronously, but rarely expressed T- and B-lymphoid cell-specific antigens. Markers for myeloid cell maturation (CD10 and CD15) were more prevalent on EBCs from low-risk MDS (refractory anemia [RA] and RA with ringed sideroblasts), whereas markers for myeloid cell immaturity (CD7 and CD117) were more prevalent on EBCs from high-risk MDS (chronic myelomonocytic leukemia, RA with excess blasts [RAEB], and RAEB in transformation) and AL-MDS. A shift to a more immature phenotype of EBCs, accompanying disease progression, was also documented by sequential phenotyping of the same patients. Further, CD7 positivity of EBCs was an independent variable for a poor prognosis in MDS. These data represent new, valuable information regarding MDS. © 2002 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: T. Yamashita, H. Tamura, C. Satoh, E. Shinya, H. Takahashi, L. Chen, A. Kondo, T. Tsuji, K. Dan, and K. Ogata Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage Clin. Cancer Res., February 1, 2009; 15(3): 770 - 777. [Abstract] [Full Text] [PDF] A. A. van de Loosdrecht, T. M. Westers, A. H. Westra, A. M. Drager, V. H. J. van der Velden, and G. J. Ossenkoppele Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry Blood, February 1, 2008; 111(3): 1067 - 1077. [Abstract] [Full Text] [PDF] K. Ogata, Y. Kishikawa, C. Satoh, H. Tamura, K. Dan, and A. Hayashi Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes Blood, August 1, 2006; 108(3): 1037 - 1044. [Abstract] [Full Text] [PDF] D. P. Steensma and J. M. Bennett The Myelodysplastic Syndromes: Diagnosis and Treatment Mayo Clin. Proc., January 1, 2006; 81(1): 104 - 130. [Abstract] [Full Text] [PDF] A. Sternberg, S. Killick, T. Littlewood, C. Hatton, A. Peniket, T. Seidl, S. Soneji, J. Leach, D. Bowen, C. Chapman, et al. Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome Blood, November 1, 2005; 106(9): 2982 - 2991. [Abstract] [Full Text] [PDF] K. Ogata, C. Satoh, M. Tachibana, H. Hyodo, H. Tamura, K. Dan, T. Kimura, Y. Sonoda, and T. Tsuji Identification and Hematopoietic Potential of CD45- Clonal Cells with Very Immature Phenotype (CD45-CD34-CD38-Lin-) in Patients with Myelodysplastic Syndromes Stem Cells, May 1, 2005; 23(5): 619 - 630. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020